Jessica Altman, MD, is a Professor in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. She also serves as Director of the Acute Leukemia Program at Robert H. Lurie Cancer Center of Northwestern University.
Dr. Altman received her medical degree from the University of Pittsburgh. She completed her residency in internal medicine at the University of Chicago and fellowship in hematology and oncology at Northwestern McGaw/Northwestern Memorial Hospital. She is board certified in hematology.
Dr. Altman's clinical and research interests include acute and chronic leukemias, anemia, myelodysplastic syndromes, and myeloproliferative diseases. She has published and presented extensively in these disease areas. Dr. Altman chairs the clinical trial audit committee of the Robert H. Lurie Comprehensive Cancer Center. She is also a member of the Northwestern Medicine Developmental Therapeutics Program, the Signal Transduction in Cancer Program, and the Hematologic Malignancies Program at the Robert H. Lurie Cancer Center. Her clinical transduction research focuses on novel targeted approaches for the treatment of acute leukemia.
Dr. Altman is a member of the American Society of Hematology and she chairs the steering committee of the AML/MDS MATTERS Program. She is active in the ECOG- ACRIN cooperative group, and serves as a member of the NCCN Acute Myeloid Leukemia Panel and the NCCN Chronic Myelogenous Leukemia Panel.
John P. Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Associate Dean for Clinical Research at the Weill Cornell Medical College. He is Executive Vice Chairman of the Weill Department of Medicine and Associate Director of the Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital, where he also serves as Attending Physician and Director of the Joint Clinical Trials Office.
An expert in hematology and oncology, Dr. Leonard is Chair of the Lymphoma Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB, ACOSOG and NCCTG), a multicenter cooperative group and key component of the National Cancer Institute’s National Clinical Trials Network. Dr. Leonard has been an elected member of the American Board of Internal Medicine Hematology subspecialty board, and he has also been elected to membership in the American Society of Clinical Investigation. He has served as Chair of the Scientific Advisory Board and Board Member of the Lymphoma Research Foundation and Board Member of the Leukemia and Lymphoma Society/New York City Chapter.
Dr. Leonard performed his undergraduate work at Johns Hopkins University and received his medical degree at the University of Virginia in Charlottesville, VA. He completed his residency in medicine at the New York Hospital - Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, NY. He completed a fellowship in hematology and oncology at Cornell, and served as the chief medical resident at the New York Hospital - Cornell Medical Center.
Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF). He facilitates and promotes myeloma research worldwide, especially in underprivileged countries.
Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He also serves as a Councilor on the Executive of the American Society of Hematology. He also recently led the ASCO guidelines for multiple myeloma.
Dr. Mikhael was previously a hematologist at Mayo Clinic Arizona where he served as Professor, Associate Dean of Graduate Medical Education and Deputy Director - Education of the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.
He specializes clinically in plasma cell disorders. Dr. Mikhael is currently the principal investigator of many clinical trials in myeloma, but his other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group, and serves on the editorial board of the Journal of Clinical Oncology.